Technical Analysis for SNDX - Syndax Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
grade D 8.86 0.57% 0.05
SNDX closed up 0.57 percent on Wednesday, September 18, 2019, on 39 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions.

Earnings due: Sep 27

*** please verify all earnings dates ***

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Up Down Down
See historical SNDX trend table...

Date Alert Name Type % Chg
20 DMA Resistance Bearish 0.00%
MACD Bullish Signal Line Cross Bullish 0.00%
Narrow Range Bar Range Contraction 0.00%
NR7 Range Contraction 0.00%
MACD Bearish Signal Line Cross Bearish 1.26%
Inside Day Range Contraction 1.26%
Down 3 Days in a Row Weakness 1.26%
20 DMA Resistance Bearish -2.21%
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup -2.21%
MACD Bullish Signal Line Cross Bullish -2.21%

Older signals for SNDX ...

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
Syndax Pharmaceuticals, Inc., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics in oncology. The company's lead product candidate is entinostat, an epigenetic therapy for treatment-resistant cancers, such as breast cancer and lung cancer, as well as other indications comprising solid tumors and hematological malignancies. Its Entinostat is an oral histone deacetylase inhibitor that targets cancer cell growth and resistance pathways that limit the effectiveness and durability of cancer therapies. The company has a collaborative research and development agreement with the National Cancer Institute; and Genentech. Syndax Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Waltham, Massachusetts.
Medicine Chemistry Cancer Clinical Medicine Solid Tumors Breast Cancer Antineoplastic Drugs Cancer Therapies Lung Cancer Pyridines Late Stage Biopharmaceutical Hematological Malignancies Benzamides Carbamates National Cancer Institute
Is SNDX a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 1 bullish, 2 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 11.11
52 Week Low 3.39
Average Volume 127,979
200-Day Moving Average 7.0683
50-Day Moving Average 9.2176
20-Day Moving Average 8.897
10-Day Moving Average 8.906
Average True Range 0.4768
ADX 16.97
+DI 14.8051
-DI 21.5613
Chandelier Exit (Long, 3 ATRs ) 8.9996
Chandelier Exit (Short, 3 ATRs ) 9.2504
Upper Bollinger Band 9.7206
Lower Bollinger Band 8.0734
Percent B (%b) 0.48
BandWidth 18.514106
MACD Line -0.1307
MACD Signal Line -0.1368
MACD Histogram 0.0061
Fundamentals Value
Market Cap 196.86 Million
Num Shares 22.2 Million
EPS -2.84
Price-to-Earnings (P/E) Ratio -3.12
Price-to-Sales 191.23
Price-to-Book 2.13
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 9.19
Resistance 3 (R3) 9.17 9.03 9.14
Resistance 2 (R2) 9.03 8.95 9.05 9.12
Resistance 1 (R1) 8.95 8.90 8.99 8.97 9.10
Pivot Point 8.81 8.81 8.83 8.82 8.81
Support 1 (S1) 8.73 8.73 8.77 8.75 8.62
Support 2 (S2) 8.59 8.68 8.60 8.60
Support 3 (S3) 8.50 8.59 8.58
Support 4 (S4) 8.53